These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 32924027)
1. Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms. Taylor J; Yeomans AM; Packham G Explor Target Antitumor Ther; 2020 Feb; 1(1):3-25. PubMed ID: 32924027 [TBL] [Abstract][Full Text] [Related]
2. PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells. Yeomans A; Lemm E; Wilmore S; Cavell BE; Valle-Argos B; Krysov S; Hidalgo MS; Leonard E; Willis AE; Forconi F; Stevenson FK; Steele AJ; Coldwell MJ; Packham G Oncotarget; 2016 Nov; 7(46):74807-74819. PubMed ID: 27579538 [TBL] [Abstract][Full Text] [Related]
3. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071 [TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells. Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253 [TBL] [Abstract][Full Text] [Related]
5. Eukaryotic translation initiation factors as promising targets in cancer therapy. Hao P; Yu J; Ward R; Liu Y; Hao Q; An S; Xu T Cell Commun Signal; 2020 Nov; 18(1):175. PubMed ID: 33148274 [TBL] [Abstract][Full Text] [Related]
6. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159 [TBL] [Abstract][Full Text] [Related]
7. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. Herzog LO; Walters B; Buono R; Lee JS; Mallya S; Fung A; Chiu H; Nguyen N; Li B; Pinkerton AB; Jackson MR; Schneider RJ; Ronai ZA; Fruman DA Br J Cancer; 2021 Mar; 124(6):1098-1109. PubMed ID: 33318657 [TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
9. Role of Eukaryotic Initiation Factors during Cellular Stress and Cancer Progression. Sharma DK; Bressler K; Patel H; Balasingam N; Thakor N J Nucleic Acids; 2016; 2016():8235121. PubMed ID: 28083147 [TBL] [Abstract][Full Text] [Related]
10. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine. Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F bioRxiv; 2023 Nov; ():. PubMed ID: 38014209 [TBL] [Abstract][Full Text] [Related]
14. Cell Fate Control by Translation: mRNA Translation Initiation as a Therapeutic Target for Cancer Development and Stem Cell Fate Control. Kim HJ Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31671902 [TBL] [Abstract][Full Text] [Related]
15. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation. Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A Genome Biol; 2014; 15(10):476. PubMed ID: 25273840 [TBL] [Abstract][Full Text] [Related]
16. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development. Kubuschok B; Trepel M Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631 [TBL] [Abstract][Full Text] [Related]
17. [Role of eukaryotic translation initiation factor 4G in tumor]. Zhang S; Huang N; Pan X; Zang JL; Guan XX; Zhang JH; Liu LC; Lei XY Sheng Li Xue Bao; 2016 Apr; 68(2):207-14. PubMed ID: 27108909 [TBL] [Abstract][Full Text] [Related]
18. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. Connor JH; Lyles DS J Virol; 2002 Oct; 76(20):10177-87. PubMed ID: 12239292 [TBL] [Abstract][Full Text] [Related]
19. Translation initiation and its relationship with metabolic mechanisms in cancer development, progression and chemoresistance. Muñoz-Ayala A; Chimal-Vega B; García-González V Adv Protein Chem Struct Biol; 2022; 132():111-141. PubMed ID: 36088073 [TBL] [Abstract][Full Text] [Related]
20. Structure and functions of the translation initiation factor eIF4E and its role in cancer development and treatment. Piserà A; Campo A; Campo S J Genet Genomics; 2018 Jan; 45(1):13-24. PubMed ID: 29396141 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]